




Response-related Prognostic Factors: The Molecular Response

Giuseppe Saglio




The amount of BCR-ABL transcripts roughly mirrors the number of residual BCR-ABL positive cells.




Amount of BCR-ABL in the PB after 3 months of imatinib therapy in the different cytogenetic-response groups

Survival Without AP/BC by Level of CyR at 12 Months on First-line Imatinib



Survival Without AP/BC by Molecular Response at 12 Months on First-line Imatinib



Possible explanation:

 the molecular analysis is more precise in discriminating between response subgroups than cytogenetic analysis


Consequence:

 The patient must be followed not only by cytogenetics but also by RQ PCR




Once reached, is MMR stable over time?


PFS by Molecular Response at 12 Months on First-line Imatinib



Although very small, a risk of losing MMR exists!




% BCR-ABL log reduction in 124 CCyR pts at 1 and 4 years: IRIS Trial





Are all molecular remissions the same?

Molecular response at 12 months by Sokal risk category




The probability to achieve MMR correlates to the Sokal risk

However, when a high or intermediate risk patient achieves a Major Molecular Remission, the risk of subsequent progression is as small as that of low risk patients. (Goldman J et al., ASH 2005)




Is the time to reach MMR relevant in terms of prognosis?

IRIS Q-PCR Study: Overall Estimated Log Reduction of *bcr-abl* with First-line Imatinib




Radich J, et al. *Blood.* 2003;102:181a. Abstract 635 and oral presentation.



Iacobucci, I. et al. J Clin Oncol; 24:454-459 2006


Association of early and late cytogenetic response with progression-free (A) and overall (B) survival



Iacobucci, I. et al. J Clin Oncol; 24:454-459 2006

RISE in BCR-ABL

- A rise in BCR-ABL of more than 2-fold identifies patients at high risk to become imatinib resistant
- In 60% of these cases, presence BCR-ABL mutations
- Mutation detection can be important






Which increase in BCR-ABL transcript level must trigger search for mutation?

Still an open question!

- 2 fold rise (Branford et al., Blood 2004)

- consecutive rises (Wang et al., Haematologica 2006)





• RQ PCR during the first year:

- To assess the response

• RQ PCR on PB every 3 months after the first year:

- to identify the late responders (continuely decreasing BCR/ABL%)
- to detect a possible rise in BCR-ABL

EVOLVING CONCEPTS IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA



RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF THE EUROPEAN LEUKEMIANET